Contrasting Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX)

Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Niagen Bioscience and Betterware de Mexico SAPI de C, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0	1	4	1	3.00
Betterware de Mexico SAPI de C	1	0	1	1	2.67

Niagen Bioscience currently has a consensus price target of $8.50, suggesting a potential upside of 295.35%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Profitability

This table compares Niagen Bioscience and Betterware de Mexico SAPI de C’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	8.37%	10.18%	7.57%
Betterware de Mexico SAPI de C	8.08%	70.20%	10.82%

Risk & Volatility

Niagen Bioscience has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Betterware de Mexico SAPI de C has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Earnings & Valuation

This table compares Niagen Bioscience and Betterware de Mexico SAPI de C”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$122.29 million	1.39	$17.38 million	$0.12	17.92
Betterware de Mexico SAPI de C	$744.00 million	0.88	$55.37 million	$1.95	8.51

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 12.7% of Betterware de Mexico SAPI de C shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 9 of the 14 factors compared between the two stocks.

About Niagen Bioscience

Niagen Bioscience, Inc. develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes. Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.

About Betterware de Mexico SAPI de C

Betterware de México, S.A.P.I. de C.V. is a consumer products company that sells household and personal-care products through a direct-selling network. Its Betterware brand focuses on practical products for home organization, storage, kitchen use, cleaning and other everyday needs, which are marketed through independent distributors and company sales channels. The company’s Mexican operations date to 1995. In 2022, Betterware acquired JAFRA, adding a beauty and personal-care business whose products include cosmetics, fragrances and skin-care items, sold through a network of consultants.